Jacobio Receives IND Approval for Aurora A Inhibitor JAB-2485 from FDA
Retrieved on:
Monday, January 17, 2022
Nature, Patient, Food and Drug Administration, News, Apoptosis, Social conditions in Honduras, SHP2, Drug resistance, Filippo Jacobio, Breast cancer, Solution, IND, Squamous cell carcinoma, Company, Environment, Multimedia, Food, Aurora A kinase, Aurora B kinase, FDA, Investigational New Drug, KRAS, Pharmaceutical industry
BEIJING and SHANGHAI and BOSTON, Jan. 16, 2022 /PRNewswire/ -- Jacobio's self-developed global first-in-class drug Aurora A inhibitor JAB-2485 received IND (Investigational New Drug) from the FDA (Food and Drug Administration) in US.
Key Points:
- BEIJING and SHANGHAI and BOSTON, Jan. 16, 2022 /PRNewswire/ -- Jacobio's self-developed global first-in-class drug Aurora A inhibitor JAB-2485 received IND (Investigational New Drug) from the FDA (Food and Drug Administration) in US.
- Jacobio plans to initiate a Phase I/IIa clinical trial in patients with advanced solid tumors in the US.
- JAB-2485 can inhibit Aurora A activity at the cellular level, induce apoptosis and inhibit tumor growth.
- Jacobio's self-developed JAB-2485 is the third Aurora A inhibitor enter into clinical stagein the United States.